Clinical Trials in Charlottesville, Virginia
2 recruiting
Showing 1–20 of 70 trials
Recruiting
Phase 3
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI)300 enrolled604 locationsNCT04181060
Recruiting
Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Recurrent Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI)46 enrolled340 locationsNCT03191149
Recruiting
Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
University of Texas Southwestern Medical Center272 enrolled50 locationsNCT02468024
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled475 locationsNCT05564377
Recruiting
Not Applicable
The Vanguard Study: Testing a New Way to Screen for Cancer
Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled36 locationsNCT06995898
Recruiting
Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)304 enrolled316 locationsNCT06096844
Recruiting
Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1149 locationsNCT04267848
Recruiting
Phase 2
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Adjustment Disorder
Reunion Neuroscience Inc100 enrolled25 locationsNCT07002034
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Chronic Lymphocytic LeukemiaMantle Cell LymphomaFollicular Lymphoma+1 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 1Phase 2
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Stage IV Lung Cancer AJCC v8Extensive Stage Lung Small Cell Carcinoma
National Cancer Institute (NCI)45 enrolled43 locationsNCT06287775
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Solid Tumor
Eisai Inc.182 enrolled58 locationsNCT04300556
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Renal Cell Carcinoma (RCC)
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled281 locationsNCT06136624
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled320 locationsNCT06136650
Recruiting
Phase 3
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Resectable Lung Non-Small Cell Carcinoma+1 more
Alliance for Clinical Trials in Oncology1,100 enrolled370 locationsNCT06632327
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Eli Lilly and Company700 enrolled353 locationsNCT06890598
Recruiting
Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
NRG Oncology3,960 enrolled1209 locationsNCT05879926
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb596 enrolled185 locationsNCT07100080
Recruiting
Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Metastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Biochemically Recurrent Prostate Carcinoma+1 more
ECOG-ACRIN Cancer Research Group804 enrolled303 locationsNCT04423211